INTRODUCTION: Phenotypic differentiation of @entity1 with @entity2335 / @entity2336 (IC/BPS) may improve our understanding of the condition, as well as the development of @entity1 -specific treatment strategies. We identified a distinct subgroup of IC/BPS @entity1 with a multiple sensitivity phenotype. METHODS: We defined @entity1 with this IC/BPS associated multiple sensitivity syndrome as having at least 3 confirmed @entity566 /sensitivities to medications and/or environmental factors and a diagnosis of IC/BPS. These IC/BPS @entity1 identified with a multiple sensitivity phenotype (cases) were compared to age-matched IC/BPS @entity1 with few or no @entity566 (controls) at a 1:2 ratio. Comparisons were undertaken using standardized case assessment parameters (age, duration of symptoms, medical history, @entity2335 Symptoms Index [ICSI] and pelvic @entity158 and urinary urgency/frequency [PUF] symptom scores, and urinary, psychosocial, organ specific, infection, neurologic/systemic, tenderness [UPOINT] categorization). RESULTS: The study consisted of 17 cases and 34 age-matched controls; the mean age was 55 and 56 years, respectively. There was statistically more medication and environmental @entity566 in the cases versus controls. Cases reported more concomitant illnesses (9.6 vs. 6.2, p < 0.001) and number of bodily systems affected (6.0 vs. 3.8, p  <= 0.001). The prevalence of @entity1744 and @entity239 was higher in the case group (p = 0.028, p  <= 0.001, respectively). Additionally, there were more reported @entity146 (p = 0.019), @entity1200 (p = 0.003), and @entity358 (p < 0.001) in the case group. UPOINT classification differed with more @entity1 in the case group being categorized in the psychosocial and neuropathic/systemic domains (p = 0.045, p = 0.007, respectively). Total UPOINT classification (out of 6) was also higher in cases than controls (4.6 vs. 3.2, p = 0.001, respectively). CONCLUSIONS: We have characterized a distinct phenotypic group of @entity1 with IC/BPS and multiple sensitivities. The limitations of our study include the retrospective case-control matching design, biases in phenotype definition, single centre @entity1 recruitment, and the lack of follow-up. Nonetheless, the observation of this specific phenotype suggests that further research in this group may help develop targeted therapeutic strategies for @entity1 with a concomitant multiple sensitivity syndrome and IC/BPS.

Multiple sensitivity phenotype in @entity2335 / XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity239 :: ('MESH:D005356', 'Disease') :: ['fibromyalgia'] @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric diseases'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergies'] @entity2336 :: ('MESH:D018856', 'Disease') :: ['bladder pain syndrome'] @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['allergic/immune diseases'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary diseases'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity2335 :: ('MESH:D003556', 'Disease') :: ['Interstitial Cystitis', 'interstitial cystitis']
@entity2336 :: (MESH:D018856,Disease) :: ['bladder pain syndrome']
